Preoperative Glycemic Control on Total Joint Arthroplasty Patient-Perceived Outcomes and Hospital Costs

J Arthroplasty. 2017 Jan;32(1):6-10. doi: 10.1016/j.arth.2016.07.002. Epub 2016 Jul 15.

Abstract

Background: The purpose of this study was to determine the influence of preoperative glycemic control in diabetic patients undergoing a primary total hip or knee arthroplasty. We wanted to study patient-perceived outcomes in the medium term, the length of stay, hospital costs, and rate of short-term postoperative complications.

Methods: One hundred twenty consecutive primary total joint arthroplasties (TJAs) performed in type 2 diabetic patients were stratified into 2 groups representing optimal and suboptimal preoperative glycemic control, based on serum levels of glycated hemoglobin (HbA1c), and those groups compared.

Results: The mean follow-up time was 5.9 years (range, 2.1-10.7 years). Both groups demonstrated improvement in all patient-perceived outcome measures after TJA, with no significant difference detected in any change of a measure between the groups. No significant difference was detected in the length of stay, hospital costs, or rate of short-term postoperative complications between the groups.

Conclusion: Preoperative glycemic control in type 2 diabetic patients undergoing TJA did not affect patient-perceived outcomes in the medium term. Optimal vs suboptimal glycemic control in these patients also had no effect on the length of stay, hospital costs, or rate of short-term postoperative complications.

Keywords: HbA(1c); complications; diabetes mellitus; hospital costs; outcomes; total joint arthroplasty.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Arthroplasty, Replacement* / adverse effects
  • Arthroplasty, Replacement* / economics
  • Diabetes Mellitus, Type 2 / blood*
  • Female
  • Glycated Hemoglobin / analysis*
  • Hospital Costs*
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Patient Reported Outcome Measures
  • Preoperative Period
  • Quality of Life
  • Recovery of Function
  • Treatment Outcome

Substances

  • Glycated Hemoglobin A